Design and Enzyme‐Targeted Assessment of 1,2,4‐Triazole–1,8‐Naphthalimide Hybrids in Drug Discovery
BioMed Research International · 2025-01 · 2025 (1)
DOI: 10.1155/bmri/6115993 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 11.08.2025. Verfasst von Nataliya Korol und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry, Educational and Research Institute of Chemistry and Ecology, Uzhhorod National University, Uzhhorod, Ukraine. Hauptthemen laut MEDLINE: Triazoles, Naphthalimides, Drug Design, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Ukraine.
Abstract (Originalsprache)
This study reports the design, synthesis, and biological evaluation of novel hybrid 1,2,4‐triazole–1,8‐naphthalimide derivatives using both classical and environmentally friendly synthetic routes. The synthetic strategy involved a multistep process starting with the preparation of triazolylthioacetic acid esters, followed by electrophilic cyclization—employing both conventional bromine and a green, bromine‐free method—and culminating in amidation reactions to yield the target compounds. Structural modifications, including the incorporation of pyridinyl and benzoate moieties, were introduced to enhance biological activity. The compounds were evaluated for antimicrobial and anti‐inflammatory activities. In antimicrobial assays, several derivatives demonstrated selective activity, with Compound 5f showing the strongest broad‐spectrum antibacterial effects, particularly against Bacillus cereus and Lactobacillus plantarum , and Compound 3e displaying notable dual‐action activity against both bacterial and fungal strains. These observations underscore the influence of specific functional groups on microbial targeting and membrane penetration. Anti‐inflammatory potential was assessed via IL‐6 inhibition using ELISA. Significant reductions in IL‐6 levels were observed for Compounds 3a , 3c , 3e , 4 , 5c , 5f , and 5g , indicating promising activity, with Compounds 5c and 3a reducing IL‐6 levels to 7 pg/mL. The complementary molecular docking studies revealed strong binding affinities for Compound 5f across multiple bacterial enzymes, suggesting effective interactions through hydrogen bonding, electrostatic, and hydrophobic forces and supporting its potential to target iron‐regulated pathways and fosfomycin resistance mechanisms. Overall, the integrative approach combining synthetic chemistry, biological assays, and computational modeling highlights the potential of these hybrid 1,2,4‐triazole derivatives as candidates for further development as antimicrobial and anti‐inflammatory agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Organic Chemistry, Educational and Research Institute of Chemistry and Ecology, Uzhhorod National University, Uzhhorod, Ukraine.
- Research Development and Educational Centre of Molecular Microbiology and Mucosal Immunology, Uzhhorod National University, Uzhhorod, Ukraine.
ORCID-Profile: Nataliya Korol
Förderung
- National Research Foundation of Ukraine
Zitieren
APA
Korol, N., Slyvka, M., Rusyn, I., Pallah, O., Burmei, S., & Bestritska, V. (2025). Design and Enzyme‐Targeted Assessment of 1,2,4‐Triazole–1,8‐Naphthalimide Hybrids in Drug Discovery. BioMed Research International, 2025(1). https://doi.org/10.1155/bmri/6115993
Vancouver
Korol N, Slyvka M, Rusyn I, Pallah O, Burmei S, Bestritska V. Design and Enzyme‐Targeted Assessment of 1,2,4‐Triazole–1,8‐Naphthalimide Hybrids in Drug Discovery. BioMed Research International. 2025;2025(1). doi:10.1155/bmri/6115993
BibTeX
@article{Korol2025,
author = {Korol, Nataliya and Slyvka, Mykhailo and Rusyn, Ivan and Pallah, Oleksandra and Burmei, Svitlana and Bestritska, Viktoriia},
title = {Design and Enzyme‐Targeted Assessment of 1,2,4‐Triazole–1,8‐Naphthalimide Hybrids in Drug Discovery},
journal = {BioMed Research International},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/bmri/6115993}
}
EUVIMED